Jenburkt Pharmaceuticals DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.69×	0.73×	0.74×	0.75×
	1.26×	1.18×	1.15×	1.18×
	23.8%	24.5%	21.5%	20.3%
	0.80×	0.84×	0.93×	0.96×
	18.8%	20.3%	19.4%	20.5%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

JENBURPH₹872.30

Jenburkt Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersBPLPHARMA KPL MAKERSL NOVARTIND PARNAXLAB SGRL SHUKRAPHAR SUNLOC

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.75	0.74	0.73	0.69
Interest Burden (Pretax/EBIT) ×	1.18	1.15	1.18	1.26
EBIT Margin %	20.29	21.49	24.53	23.81
Asset Turnover ×	0.96	0.93	0.84	0.80
ROE (owners' profit / average owners' equity) %	20.53	19.43	20.25	18.84

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.